BCM
GNCA

Bridgeway Capital Management’s Genocea Biosciences, Inc. GNCA Stock Holding History

Bridgeway Capital Management’s Portfolio GNCA Stock Details GNCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-18,875
Closed -$220K – 1473
2017
Q3 		$220K Hold
18,875
– – ﹤0.01% 1266
2017
Q2 		$788K Hold
18,875
– – 0.01% 920
2017
Q1 		$920K Buy
18,875
+4,000
+27% +$156K 0.01% 844
2016
Q4 		$490K Hold
14,875
– – 0.01% 1096
2016
Q3 		$609K Buy
14,875
+3,750
+34% +$147K 0.01% 1001
2016
Q2 		$365K Sell
11,125
-4,900
-31% -$180K 0.01% 1168
2016
Q1 		$992K Buy
16,025
+8,000
+100% +$254K 0.02% 778
2015
Q4 		$338K Buy
8,025
+4,900
+157% +$234K 0.01% 1177
2015
Q3 		$171K Hold
3,125
– – ﹤0.01% 1332
2015
Q2 		$343K Hold
3,125
– – 0.01% 1209
2015
Q1 		$297K Sell
3,125
-627
-17% -$44.2K 0.01% 1262
2014
Q4 		$210K Buy
3,752
+1,500
+67% +$102K ﹤0.01% 1299
2014
Q3 		$163K Buy
+2,252
New +$247K ﹤0.01% 1364

Other funds holding GNCA

PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NC
Northpointe Capital Bloomfield Hills, Michigan $258M AUM 1.97% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
AA
AlphaMark Advisors Ft. Wright, Kentucky $231M AUM 19.98% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Bridgeway Capital Management's GNCA Position: Q4 2017 in Review

Bridgeway Capital Management sold out of Genocea Biosciences, Inc. (GNCA) in Q4 2017, closing a stake of 18,875 shares — an estimated $220K sold.

Bridgeway Capital Management first reported a position in GNCA in Q3 2014 and held it in 13 quarters. The position peaked at $992K in Q1 2016. 56 funds tracked by Wall St. Rank hold GNCA as of Q4 2017.

  • Bridgeway Capital Management reported no remaining Genocea Biosciences, Inc. position as of Q4 2017 after selling out during the quarter.
  • Bridgeway Capital Management sold 18,875 Genocea Biosciences, Inc. shares in Q4 2017, an estimated $220K.
  • Bridgeway Capital Management first reported a position in Genocea Biosciences, Inc. in Q3 2014 and held it in 13 quarters.
  • Bridgeway Capital Management's Genocea Biosciences, Inc. position peaked at $992K in Q1 2016.
  • 56 funds tracked by Wall St. Rank held Genocea Biosciences, Inc. as of Q4 2017.

Based on Bridgeway Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.